Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

Corporate Investor Presentation

Rigel Corporate Investor Presentation
More »
Recent News
DateTitle 
11/06/18
Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the third
11/01/18
Data related to fostamatinib accepted for oral presentation and two poster presentations SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that two-year safety and efficacy data from its FIT Phase 3 extension study (FIT3) for the
10/30/18
SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2018 financial results after market close on Tuesday, November 6 , 2018.  Rigel senior management will follow the announcement with a live

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.
What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site